Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Hiram Maldonado Rivera

Endocrinology, Diabetes & Metabolism Bayamon, PR Medical Doctor

NPI 1871049536 CMS profile 7226430

Calle Betances #40, Canton Mall Local B3 2Nd Floor, Bayamon, PR 00961

Open in the dashboard

General payments

$6,700

272 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Hiram Maldonado Rivera of Bayamon, PR is reported in the CMS Open Payments database as having received $6,700 across 272 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 72nd percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $249 6
2024 General $2,861 137
2023 General $2,012 89
2022 General $761 19
2021 General $334 13
2019 General $483 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hiram Maldonado Rivera
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to Hiram Maldonado Rivera were reported at $249. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year Hiram Maldonado Rivera Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $483 $494 $123–$2,253 $163
2020 $0 $335 $85–$1,841 $114
2021 $334 $398 $88–$1,981 $132
2022 $761 $364 $88–$1,568 $149
2023 $2,012 $420 $113–$1,614 $160
2024 $2,861 $440 $121–$1,646 $164
2025 $249 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $753 31 payments
  2. Lilly USA, LLC $690 37 payments
  3. Amgen Inc. $683 17 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $479 21 payments
  5. Kyowa Kirin, Inc. $368 9 payments
  6. Sanofi-Aventis U.S. LLC $342 10 payments
  7. Xeris Pharmaceuticals, Inc. $300 18 payments
  8. Corcept Therapeutics $298 17 payments
  9. Mannkind Corporation $260 9 payments
  10. Radius Health, Inc. $222 14 payments
  11. Other $2,305 89 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,688 271 payments
  2. Education $11 1 payment
Products named General payments · program years 2019–2025
  1. Ozempic $470 22 payments
  2. RYBELSUS $430 20 payments
  3. Crysvita $344 8 payments
  4. MOUNJARO $329 18 payments
  5. JARDIANCE Diabetes $311 12 payments
  6. Korlym $298 17 payments
  7. JARDIANCE Diabetes $285 15 payments
  8. Prolia $220 6 payments
  9. Omnipod $209 4 payments
  10. t:slim X2 Insulin Pump with Control-IQ $208 6 payments
  11. Other $3,911 173 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

272 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Endocrinology, Diabetes & Metabolism in Puerto Rico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record